title: [Clinical analysis of 23 gynecologic carcinoma patients with brain metastasis].
abstract: OBJECTIVE
  To explore the clinicopathological characteristics and treatments of brain metastasis (BM) in patients with gynecologic carcinoma.
  
  
  METHODS
  Twenty-three pathologically confirmed patients with gynecologic carcinoma who had brain metastasis between February 2008 and October 2012 were analyzed retrospectively.
  
  
  RESULTS
  The primary carcinoma was cervical cancer in 5 patients, endometrial carcinoma in 8 patients and ovarian cancer in 10 patients, which accounted for 1.81% (5/276), 2.10% (8/380) and 2.67% (10/374) of patient with the same diagnosis of the same period, respectively.Among them, 91.3% (21/23) patients had heterochronous BM.Single BM was documented in 52.2% (12/23) patients.Besides, 78.2% (18/23) BM located in cerebrum.At the time of BM, 91.3% (21/23) patients had symptoms of central nervous system, in which headache ranked the top (90.4%). Altogether, thirteen patients had extracranial metastasis, in which 9 of them had metastasis of the lung.The median post-brain-metastasis survival (mPBMS) for the recursive partitioning analysis (RPA) classes Ⅰ-Ⅲ was 54 months, 9 months and 1 month, respectively (P<0.01). None of surgery, radiotherapy or chemotherapy treatment was proven to have prognosis-improving ability either in single variant or multivariate analysis.However, in patients with extracranial metastasis, chemotherapy could significantly improve their mPBMS (P<0.05).
  
  
  CONCLUSIONS
  The incidence of brain metastasis in patients with cervical cancer, endometrial carcinoma, and ovarian cancer increased gradually.RPA was valuable for a prognostic assessment in gynecologic carcinoma patients with BM.Chemotherapy could significantly improve prognosis of gynecologic carcinoma patients with BM if extracranial metastasis was presented.
authors.affiliation: Department of Gynecology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China.
authors.forename: J X
authors.initials: JX
authors.lastname: Zhang
authors.forename: S Z
authors.initials: SZ
authors.lastname: Wang
authors.forename: B
authors.initials: B
authors.lastname: Li
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Zhang
mesh_terms: D001921:Brain / Q000473:pathology*; D001932:Brain Neoplasms / Q000401:mortality* / Q000556:secondary* / Q000628:therapy; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D006801:Humans; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy